The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa

Makepeace, B. L., Babayan, S. A. , Lustigman, S. and Taylor, D. W. (2015) The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa. Expert Review of Vaccines, 14(9), pp. 1163-1165. (doi: 10.1586/14760584.2015.1059281) (PMID:26091691)

Full text not currently available from Enlighten.


Onchocerciasis or river blindness is a neglected parasitic disease causing severe dermatitis and visual impairment, predominantly in Africa. Historically, onchocerciasis control targeted vector breeding sites, but the current strategy relies on mass administration of a single drug, ivermectin. As programmatic goals shift from reducing public health impact to active elimination, sole reliance on ivermectin is threatened by contraindications in areas coendemic for loiasis, an inability to break transmission in some foci, and the emergence of drug resistance. Here, we argue that prophylactic and therapeutic vaccines would accelerate elimination efforts and safeguard the enormous strides made in onchocerciasis control. These vaccines could be based on one or more of three lead candidates identified by a newly formed transatlantic partnership, The Onchocerciasis Vaccine for Africa Initiative.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Babayan, Dr Simon
Authors: Makepeace, B. L., Babayan, S. A., Lustigman, S., and Taylor, D. W.
College/School:College of Medical Veterinary and Life Sciences > School of Biodiversity, One Health & Veterinary Medicine
Journal Name:Expert Review of Vaccines
Publisher:Taylor and Francis
ISSN (Online):1744-8395

University Staff: Request a correction | Enlighten Editors: Update this record